MetaVia (MTVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The annual meeting will be held virtually on June 8, 2026, with voting available online, by mail, or by proxy.
Five proposals are up for vote: election of two Class I directors, ratification of the auditor, approval of a reverse stock split, amendment to the equity plan, and potential adjournment.
The board unanimously recommends voting in favor of all proposals.
Forward-looking statements highlight risks, uncertainties, and evolving circumstances that may impact future results.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I directors for three-year terms.
Proposal 2: Ratify BDO USA, P.C. as independent auditor for 2026.
Proposal 3: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-22, at board discretion.
Proposal 4: Approve an amendment to the 2022 Equity Incentive Plan to add 200,000 shares.
Proposal 5: Authorize adjournment of the meeting if more votes are needed for Proposals 3 and 4.
Board of directors and corporate governance
The board consists of seven members, with staggered three-year terms.
Board leadership is separated between the Chair and CEO roles.
All directors except the CEO are considered independent under Nasdaq and SEC rules.
Committees include audit, compensation, and nominating/governance, each with defined responsibilities and independent members.
Directors are encouraged to attend annual meetings; all attended in 2025.
Latest events from MetaVia
- Annual meeting to vote on director elections, reverse split, equity plan, and auditor ratification.MTVA
Proxy filing15 Apr 2026 - Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026 - Biotech seeks $6M via unit offering to fund clinical programs, with significant dilution risk.MTVA
Registration Filing12 Jan 2026 - Biotech seeks $12.8M via unit offering to fund MASH/obesity drug trials amid ongoing losses.MTVA
Registration Filing5 Jan 2026 - 14M shares registered for resale after private placement; biotech faces ongoing losses and key risks.MTVA
Registration Filing16 Dec 2025 - Key votes include director elections, a reverse stock split, and share issuance approval tied to Dong-A.MTVA
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, reverse split, and major share issuance.MTVA
Proxy Filing2 Dec 2025